These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38966171)

  • 1. Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities.
    Trevisi E; Sessa C; Colombo I
    Explor Target Antitumor Ther; 2024; 5(3):627-640. PubMed ID: 38966171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis.
    Karimi F; Azadbakht O; Veisi A; Sabaghan M; Owjfard M; Kharazinejad E; Dinarvand N
    Med Oncol; 2023 Aug; 40(9):265. PubMed ID: 37561363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential clinical utility of liquid biopsies in ovarian cancer.
    Zhu JW; Charkhchi P; Akbari MR
    Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.
    Chen Q; Zhang ZH; Wang S; Lang JH
    Onco Targets Ther; 2019; 12():11517-11530. PubMed ID: 31920340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Applications of Liquid Biopsies in Ovarian Cancer.
    Chauhan US; Kohale MG; Jaiswal N; Wankhade R
    Cureus; 2023 Dec; 15(12):e49880. PubMed ID: 38174205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy in ovarian cancer.
    Giannopoulou L; Lianidou ES
    Adv Clin Chem; 2020; 97():13-71. PubMed ID: 32448432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
    Terp SK; Stoico MP; Dybkær K; Pedersen IS
    Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond.
    Sharma T; Nisar S; Masoodi T; Macha MA; Uddin S; Akil AA; Pandita TK; Singh M; Bhat AA
    Adv Protein Chem Struct Biol; 2023; 133():85-114. PubMed ID: 36707207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy for ovarian cancer using circulating tumor cells: Recent advances on the path to precision medicine.
    Yang J; Cheng S; Zhang N; Jin Y; Wang Y
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188660. PubMed ID: 34800546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragmentomics features of ovarian cancer.
    Chao X; Kai Z; Wu H; Wang J; Chen X; Su H; Shang X; Lin R; Huang L; He H; Lang J; Li L
    Int J Cancer; 2024 May; ():. PubMed ID: 38769763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code.
    Cammarata G; Barraco N; Giusti I; Gristina V; Dolo V; Taverna S
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.
    Singh A; Gupta S; Sachan M
    Front Cell Dev Biol; 2019; 7():182. PubMed ID: 31608277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125.
    Minato T; Ito S; Li B; Fujimori H; Mochizuki M; Yamaguchi K; Tamai K; Shimada M; Tokunaga H; Shigeta S; Sato I; Shima H; Yamada H; Yaegashi N; Yasuda J
    Gynecol Oncol Rep; 2021 Nov; 38():100847. PubMed ID: 34557579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.
    Ghose A; McCann L; Makker S; Mukherjee U; Gullapalli SVN; Erekkath J; Shih S; Mahajan I; Sanchez E; Uccello M; Moschetta M; Adeleke S; Boussios S
    Ther Adv Med Oncol; 2024; 16():17588359241233225. PubMed ID: 38435431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision gynecologic oncology: circulating cell free DNA epigenomic analysis, artificial intelligence and the accurate detection of ovarian cancer.
    Bahado-Singh RO; Ibrahim A; Al-Wahab Z; Aydas B; Radhakrishna U; Yilmaz A; Vishweswaraiah S
    Sci Rep; 2022 Nov; 12(1):18625. PubMed ID: 36329159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.
    Gao Y; Zhou N; Liu J
    Cancer Control; 2024; 31():10732748241255548. PubMed ID: 38764160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Applications of Liquid Biopsy in Colorectal Cancer Screening: Current Challenges and Future Perspectives.
    Galoș D; Gorzo A; Balacescu O; Sur D
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.
    Gattuso G; Crimi S; Lavoro A; Rizzo R; Musumarra G; Gallo S; Facciponte F; Paratore S; Russo A; Bordonaro R; Isola G; Bianchi A; Libra M; Falzone L
    Noncoding RNA; 2022 Aug; 8(4):. PubMed ID: 36005828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of the L-arginine/nitric oxide pathway in ovarian cancer: metabolic biomarkers and biological implications.
    Chen L; Tang Q; Zhang K; Huang Q; Ding Y; Jin B; Liu S; Hwa K; Chou CJ; Zhang Y; Thyparambil S; Liao W; Han Z; Mortensen R; Schilling J; Li Z; Heaton R; Tian L; Cohen HJ; Sylvester KG; Arent RC; Zhao X; McElhinney DB; Wu Y; Bai W; Ling XB
    BMC Cancer; 2023 Sep; 23(1):844. PubMed ID: 37684587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.